Lazard Capital Upgrades Transcept Pharmaceuticals (TSPT) to Buy, $22 Price Target
Tweet
Share
E-mailGet Alerts TSPT Hot Sheet
Price: $1.70 --0%
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Lazard Capital upgraded shares of Transcept Pharmaceuticals (NASDAQ: TSPT) to a Buy rating from its previous rating of Neutral. The firm has set its price target on the shares at $22.00.
For more ratings news on Transcept Pharmaceuticals click here and for the rating history of Transcept Pharmaceuticals click here.
Shares of Transcept Pharmaceuticals closed at $8.08 yesterday.
For more ratings news on Transcept Pharmaceuticals click here and for the rating history of Transcept Pharmaceuticals click here.
Shares of Transcept Pharmaceuticals closed at $8.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Walmart (WMT) to Buy
- Baird Upgrades Parsons Corp. (PSN) to Outperform
- BNP Paribas Exane Upgrades Pony AI Inc (PONY) to Outperform
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
